title: Doxazosin treatment in patients with prostatic obstruction. A double-blind placebo-controlled study.
abstract: The safety and efficacy of the selective alpha 1-blocking agent doxazosin 4 mg once daily in the symptomatic treatment of benign prostatic hyperplasia were evaluated in a randomized, double-blind and placebo-controlled 9-week study of 100 patients. By patients' overall assessment of voiding difficulties, 79% in the doxazosin group (DG) and 44% in the placebo group (PG) reported improvement (p = 0.001). In the DG, improvement was noted in 63% of obstructive symptoms compared to 32% in the PG (p = 0.015), whereas improvement was noted in 76% and 45%, respectively, of irritative symptoms (p = 0.12). Daytime frequency was reduced by 1.5 in the DG and increased by 0.3 in the PG (p = 0.001), and nocturia was reduced by 1.1 and 1.0, respectively (p = 0.12). Maximum urinary flow rate was improved by 1.5 ml/s in the DG, while it deteriorated by 0.3 ml/s in the PG (p = 0.11). Considering postvoid residual urine volume, cystometry variables (first sensation and bladder capacity) and adverse events there was no difference between the two groups. In conclusion, doxazosin 4 mg once daily is safe and effective in relieving symptoms in patients with BPH.
authors.affiliation: Department of Surgery K, Randers Central Hospital, Denmark.
authors.forename: M M
authors.initials: MM
authors.lastname: Christensen
authors.forename: J
authors.initials: J
authors.lastname: Bendix Holme
authors.forename: P C
authors.initials: PC
authors.lastname: Rasmussen
authors.forename: F
authors.initials: F
authors.lastname: Jacobsen
authors.forename: J
authors.initials: J
authors.lastname: Nielsen
authors.forename: J P
authors.initials: JP
authors.lastname: Nørgaard
authors.forename: S
authors.initials: S
authors.lastname: Olesen
authors.forename: I
authors.initials: I
authors.lastname: Noer
authors.forename: H
authors.initials: H
authors.lastname: Wolf
authors.forename: S E
authors.initials: SE
authors.lastname: Husted
mesh_terms: D000368:Aged; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D017292:Doxazosin / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D001748:Urinary Bladder Neck Obstruction / Q000188:drug therapy*; D014563:Urodynamics / Q000187:drug effects
chemical_list: D017292:Doxazosin